Thromboxane A2 (TXA2) biosynthesis pathway (TXA2 pathway)

The Thromboxane A2 (TXA2) biosynthesis pathway is a critical enzymatic cascade within the arachidonic acid metabolism system, primarily responsible for the production of TXA2, a potent mediator of platelet activation and vascular tone [StatPearls, 2023]. The pathway begins with the liberation of arachidonic acid from cell membrane phospholipids by phospholipase A2, which is then converted into the intermediate prostaglandin H2 (PGH2) by the enzymes cyclooxygenase-1 (COX-1) or cyclooxygenase-2 (COX-2) [PubMed, 2021]. The final step is catalyzed by thromboxane A synthase 1 (TBXAS1), which converts PGH2 into TXA2 [UniProt, 2024]. TXA2 exerts its effects by binding to the thromboxane prostanoid (TP) receptor, leading to rapid platelet aggregation and smooth muscle contraction [NIH, 2022]. Dysregulation of this pathway is heavily implicated in the pathogenesis of arterial thrombosis, myocardial infarction, and stroke [Wikipedia, 2024]. Pharmacological intervention typically involves the use of aspirin, which irreversibly inhibits COX-1 to prevent TXA2 formation, or specific thromboxane synthase inhibitors like ozagrel [PubChem, 2023]. These therapies are essential for secondary prevention in patients with cardiovascular disease, although they carry risks such as increased bleeding and gastrointestinal complications [StatPearls, 2023].

Other names

TXA2 synthesis pathwayThromboxane synthase pathwayArachidonic acid-thromboxane cascade

Inhibition of Cyclooxygenase-1 (COX-1) or Thromboxane A synthase (TBXAS1) to prevent the conversion of arachidonic acid or prostaglandin H2 into thromboxane A2.